German pharmaceutical giant China biopharmaceutical contract production business launched in an all-round way

[China Pharmaceutical network industry trends] over the past four years, the German pharmaceutical giant China biopharmaceutical base was officially opened It is reported that the base is located in Zhangjiang High Tech Park, Pudong, Shanghai At present, a 2000 liter disposable bioreactor production line is in operation The formal operation of the base marks the full launch of the contract production business of China's biopharmaceutical industry In recent years, the compound growth rate of domestic biomedical industry scale has reached about 20% every year, with vigorous development, and a number of innovative enterprises with independent research and development capabilities have emerged However, due to the lack of funds and production line support, many enterprises are forced to sell new drug technology to other enterprises with production capacity at low prices The biopharmaceutical contract production mode is just to solve the "production bottleneck" of R & D enterprises On the premise of no change in ownership, innovative enterprises can entrust high-level enterprises to carry out OEM, so as to help new drugs in research realize industrialization and value maximization Boehringer Ingelheim is the pioneer of CMO project in China In 2013, bringer Ingelheim signed a strategic cooperation agreement with Shanghai Zhangjiang Biological Base Development Co., Ltd., and both sides announced the establishment of a biological pharmaceutical base with international pharmaceutical production quality management norms After 4 years, the base was officially opened At present, the base has reached cooperation with a number of domestic R & D enterprises, including Baiji Shenzhou, to provide clinical trial support for anti-tumor and other biological new drugs The design, construction and operation system of the base meet the current international high standards, and have the qualification and ability to supply the biomedical market to all countries in the world Wang Lanzhong, general manager of Shanghai Zhangjiang biomedical Base Development Co., Ltd., said that the completion and operation of the base can introduce professional processes, technologies, standards and experience that are in line with international standards for China, accelerate the industrialization of innovation achievements of R & D-oriented enterprises, and promote the further and rapid development of China's biomedical industry.